@WallStSai@ResearchPulse1 I would rather purchase viking if I had to choose. I can only imagine the potential for oral vk2735 with novos third generation already in place.
@WallStSai@ResearchPulse1 Personally I would rather focus on trying to make Efruxifermin an oral option with snac. A shorter plasma trial to make it orally could save a lot of money for novo. In addition it could be added to zena or sema.
@RVADreams73@ResearchPulse1@JCanNuSH Ip theft is simply the problem here. Drugs will go generic eventually, but the current price is what’s driving innovation and the insentivs to make new and better drugs.
@BigBeedaBig@bioinvestor24 This is why your not running a big company and he is. Everything can be a bad purchase if you pay to much. And current sp does not signal what a buyout may be priced at
@LAlbertsen66721@fastmoney911@investseekers I bought more since i believed it was overdone, however the guidance was as good as any. In fact it would probably be better if they just did not guide. And there were no «wonder news». The cagrisema trail could be bad, as it looks, increasing dose does not mean better wl.
@ObsvRetardation@woidebaben@bioinvestor24 The retard keeps retarding I guess. Novo has plenty of time before they need to make an offer, even if the maintenance trail data is released soon.
@ResearchPulse1@bioinvestor24 Regardless, the peptide will only be sucsessfull if its tolarable, we already know its very efficacious. Mby sutible for oral?
@BarnyardBull72 This is a perfect example of how oral peptides is almost impossible to get right. Zena and Sema will arguably reach 5% potency and will be suitable for decades to come, this with just snac.